ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferon"

  • Abstract Number: 1807 • ACR Convergence 2024

    Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus

    Takehiro Hirayama1, Hyota Takamatsu2 and Atsushi Kumanogoh3, 1Osaka university, ibaraki city, Japan, 2National Hospital Organization Osaka Minami Medical Center, kawachinagano, Japan, 3Osaka University, Osaka, Japan

    Background/Purpose: This study aimed to identify drugs that can inhibit both type I interferon (IFN-I) production and abnormal B-cell maturation and to elucidate the therapeutic…
  • Abstract Number: 2678 • ACR Convergence 2024

    History of Cutaneous Lupus Promotes Blood and Skin Interferon Signatures in SLE Patients

    Svenja Henning1, Lam Tsoi2, Craig Dobry2, Celine Berthier2, Benjamin Klein2, Amy Hurst2, Rachael Wasikowski3, Johann Gudjonsson2 and J. Michelle Kahlenberg2, 1University of Groningen, Groningen, Netherlands, 2University of Michigan, Ann Arbor, MI, 3Michigan, Dept. of Dermatology, Ann Arbor, MI

    Background/Purpose: Cutaneous lupus (CLE) can present in isolation or as one of the most common manifestations of systemic lupus erythematosus (SLE). Interferon (IFN) stimulated genes…
  • Abstract Number: 0633 • ACR Convergence 2024

    Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus

    Wenyan Miao1, Digna de Bruin2, Cedric Arisdakessian1, Jannik Rousel2, Jared Steranka1, Matthijs Moerland2, Eric Jacobson1, Mehrnaz Gharaee-Kermani3, Liyang Diao1, Craig Dobry3, Nafeeza Hafeez1, Brian Desrosiers1, J. Michelle Kahlenberg3, Heike Keilhack1, Robert Rissmann2, Keith M Wilcoxen1 and Tessa Niemeyer-van der Kolk2, 1Rome Therapeutics, Boston, MA, 2Centre for Human Drug Research, Leiden, Netherlands, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
  • Abstract Number: 1537 • ACR Convergence 2024

    Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases

    Kelly A. Pike1, Nadine Fradet1, Samuel Gaudreault1, Alexander M Skeldon2, Ramsay E. Beveridge2, Patrick Cyr2, Nicolas Sgarioto2, Philippe Le Gros3, Eleftheria Seliniotakis2, Valerie Dumais2, Jacklyn Smith2, James I.P Stewart2, Mehrnaz Gharaee-Kermani4, Michelle J Kahlenberg4 and Michael A. Crackower2, 1Ventus Therapeutics, Saint-Laurent, QC, Canada, 2Ventus Therapeutics, Saint-Laurent, Canada, 3Ventus Therapeutics, Montreal, QC, Canada, 4University of Michigan, Ann Arbor, MI

    Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…
  • Abstract Number: 1828 • ACR Convergence 2024

    SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling

    Christopher Wasson1, Stefano Di Donato2, Rebecca Ross3, Vishal Kakkar4 and Francesco Del Galdo1, 1University of Leeds, Leeds, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 3Medicine and Health, University of Leeds, Leeds, United Kingdom, 4LIRMM University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis is an autoimmune disease which is characterized by fibrosis of the skin and the internal organs with variable severity. Type I interferon…
  • Abstract Number: 0666 • ACR Convergence 2024

    Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy

    Cuiling Fan1, Shixian Chen2 and Juan Li1, 1Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China (People's Republic), 2Nanfang Hospital, Southern Medical University, guangzhou, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. BAFF/APRIL-targeted therapy exert therapeutic effects through the inhibition of B-cell activating factor (BAFF) and a…
  • Abstract Number: 1553 • ACR Convergence 2024

    Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)

    Torsten Witte1, Ruth Fernandez Ruiz2, Nadezda Abramova3, Dominika Weinelt3, Flavie Moreau4, Lena Klopp-Schulze5, Jamie Shaw6, Deborah Denis7 and Joerg Wenzel8, 1Dept of Immunology and Rheumatology, Hannover, Germany, 2Global Clinical Development, EMD Serono, Billerica, MA, 3Global Patient Safety, the healthcare business of Merck KGaA, Darmstadt, Germany, 4Global Biostatistics, EMD Serono, Billerica, MA, 5Quantitative Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany, 6Companion Diagnostics and Biomarker Strategy, EMD Serono, Billerica, MA, 7EMD Serono, Rockland, MA, 8Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany

    Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…
  • Abstract Number: 1831 • ACR Convergence 2024

    Role of Long Non-Coding RNA H19 in Mediating Skin Fibrosis in Systemic Sclerosis

    Begoña Caballero-Ruiz1, Christopher Wasson2, Rebecca Ross3 and Francesco Del Galdo2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3Medicine and Health, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Systemic Sclerosis (SSc) is an immune driven condition leading to skin fibrosis, as well as internal organs. Dermal fibroblasts are the key cellular elements…
  • Abstract Number: 0815 • ACR Convergence 2024

    Interferon-stimulated Gene Expression in Non-lesional Skin Is Similarly Elevated in Incomplete SLE and SLE

    Svenja Henning1, Lam Tsoi2, Benjamin Klein2, Celine Berthier2, Joseph Kirma2, Rachael Wasikowski3, Gilles Diercks4, Barbara Horvath1, Hendrika Bootsma5, Johann Gudjonsson2, Johanna Westra4, Karina de Leeuw6 and J. Michelle Kahlenberg2, 1University of Groningen, Groningen, Netherlands, 2University of Michigan, Ann Arbor, MI, 3Michigan, Dept. of Dermatology, Ann Arbor, MI, 4University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, 5Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 6University Medical Center Groningen, Groningen, Groningen, Netherlands

    Background/Purpose: Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria are referred to as incomplete SLE (ILE). These patients are…
  • Abstract Number: 1556 • ACR Convergence 2024

    Efficacy and Safety of Anifrolumab Across Organ Domains of Systemic Lupus Erythematosus. A Systematic Review and Meta-Analysis

    Mohammad Taha1, Yomna W Mahmoud1, Mohammad Ramadan1, sarah nasir1, Mariam salah1, Yassin shenawy2, doaa gadelrab1 and Muhammad abuawwad1, and ARC team, 1Cairo university, Cairo, Egypt, 2cairo, cairo, Egypt

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Anifrolumab is a monoclonal antibody that antagonizes type I interferon receptors,…
  • Abstract Number: 1837 • ACR Convergence 2024

    Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment

    Addison Pacheco1, Zoya Qaiyum2, Fataneh Tavasolian3, Melissa Lim4, Michael Tang1 and Robert Inman1, 1University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, Toronto, ON, Canada, 3Krembil Research Institute - the University Health Network, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Our study aims to discriminate immune profiles between secukinumab responders (SEC-R) and nonresponders (SEC-NR) in axial spondyloarthritis (axSpA) patients before biologic treatment.Methods: CD45RO+CD45RA-CD4+ T…
  • Abstract Number: 0839 • ACR Convergence 2024

    Comprehensive Single-cell Analysis Reveals Interferon Pathway Activation and Aberrant B Cell Dynamics in APS Autoimmunity

    Haoyu Pan, Xiaohan Wei, Jinyi Qian, Shuyi Yu, Zhixia Yang, Zetao Ding, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized with the presence of pathogenic antiphospholipid antibodies (aPL) by autoreactive B cells. However, it remains…
  • Abstract Number: 1646 • ACR Convergence 2024

    A Novel E3 Ligase of GILZ: Validation of a Steroid-sparing Therapeutic Target in SLE

    Iolanda Miceli1, Rochelle Sherlock2, Pamela Hall2, IanIan Cheang2, Akshay D'Cruz3, Taylah Bennett2, Terry Lim Kam Sian2, Rangi Kandane-Rathnayake4, Eric Morand5 and Sarah Jones2, 1Monash University, Glen Iris, Victoria, Australia, 2Monash University, Melbourne, Australia, 3Monash University, Me, Australia, 4Monash University, Clayton, Victoria, Australia, 5School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia

    Background/Purpose: SLE is primarily mediated by B cell dysregulation on a background of type I interferon (IFN) activation. This multi-faceted nature of immune defects in…
  • Abstract Number: 2077 • ACR Convergence 2024

    Comparison of Janus Kinase Inhibitors to Block the Type I and II Interferon Pathways in Human Myoblasts

    Travis Kinder and James Inglese, National Institutes of Health, Rockville, MD

    Background/Purpose: The family of Janus kinases (JAK1, JAK2, JAK3, TYK2) mediate signal transduction from cytokine receptors through phosphorylation and activation of intracellular signaling pathways and…
  • Abstract Number: 0887 • ACR Convergence 2024

    Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort

    Anastasia-Vasiliki Madenidou1, Gillian Rice2, Terence Garner3, Sarah Dyball4, Alice Chieng5, Ben Parker6, Tracy Briggs7, Adam Stevens3 and Ian Bruce8, 1Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 2Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, 3Division of Developmental Biology and Medicine, Faculty of Biology, Medicine and Health, University of Manchester and Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom, 4Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK, Manchester, United Kingdom, 5Department of Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, Manchester, United Kingdom, 6Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 7Division of Evolution, Infection and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, 8Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Connective tissue diseases (CTDs) are a family of heterogeneous autoimmune diseases with overlapping clinical features. Not all patients with features suggestive of a mendelian…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology